Abstract
Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.3389/fphar.2024.1398879
Copy DOIJournal: Frontiers in pharmacology | Publication Date: May 9, 2024 |
License type: CC BY 4.0 |
Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.
Join us for a 30 min session where you can share your feedback and ask us any queries you have